Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial

Pujade-Lauraine, E.Selle, F.Scambia, G.Asselain, B.Marme, F.Lindemann, K.Colombo, N.Madry, R.Glasspool, R. M.Dubot, C.Oaknin, A.Zamagni, C.Heitz, F.Gladieff, L.Rubio-Perez, M. J.Scollo, P.Blakeley, C.Shaw, B.Ray-Coquard, I. L.Redondo, A.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/25339enMaintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trialconference outputopen access10.1016/j.annonc.2021.08.21101569-8041https://doi.org/10.1016/j.annonc.2021.08.2110700527703509